Genmab

International biotech company dedicated to improving the lives of people with cancer & other serious diseases through antibodies.

[Genmab @Genmab]

During this edition of #AntibodyHour 🕙, we spotlight our colleague Iris Kolder, Director, Translational and Clinical Data Science.

Iris shares what motivates her work to bring medicines to patients, how she sees the people behind the data, and how her experience as a cancer survivor brings personal meaning to what she does each day.

#AntibodyScience

[Genmab @Genmab]

#NewsUpdate: Topline results from a phase 3 study in newly diagnosed diffuse large B-cell #lymphoma (#DLBCL) are now available for our therapy in partnership with @abbvie.

Learn more: https://t.co/KHYFxhHwSr

[Genmab @Genmab]

At #IGCS2026, we shared new Phase 1/2 data evaluating one of our investigational therapies in #OvarianCancer.

These results add to the growing body of evidence supporting our clinical program in #GynecologicCancers.

Hear from Dr. Elizabeth Lee.

Learn more: https://t.co/9twKySXWCm.

[Genmab @Genmab]

This #WorldLymphomaDay, we’re sharing how we’re working to change the course of care for patients and the larger #lymphoma community.

[Genmab @Genmab]

Today, Genmab colleagues participated in Global Volunteer Day: volunteering 3000+ hours for 50+ local charities in the communities where we live and work.

Learn more here: https://t.co/qwEWF7u6p7.

#CommunityAtGenmab

[Genmab @Genmab]

We’re heading to #SOHO2026!

Connect with Genmab colleagues at the 14th Annual @SocietyofHemOnc Meeting and visit Booth #176 to learn more about our innovative antibody science and investigational therapies.

#Hematology

[Genmab @Genmab]

We are excited to announce that Genmab is now on Facebook and Instagram! These channels offer new ways to share our story and connect with our community.

Follow along to explore our science, our people and how we're committed to our goal of improving the lives of people with cancer and other serious diseases.

Facebook: https://t.co/wqLVD8VRpR.

Instagram: https://t.co/IjD1SdvQmE

[Genmab @Genmab]

Cervical cancer was one of the most common cancers affecting women in the United Kingdom aged 15-44 in 2023. (3)
We’re pushing for change and are committed to improving outcomes.

#CervicalCancer #WomensHealth

[Genmab @Genmab]

How can antibody science enable more targeted, personalized approaches in oncology?

In this #AntibodyHour 🕙, Marije Overdijk, Head of Early Translational Medicine and Research, shares how her team advances promising antibody medicines from the research bench toward clinical proof of concept.

#AntibodyHour #AntibodyScience

[Genmab @Genmab]

#InvestorUpdate: We announced our earnings report for the first half of 2026, highlighting strong execution against our strategic priorities and a strong financial foundation to support long-term growth.

Learn more and tune in to our investor call: https://t.co/59Jde4gmG9.

#Biotech #Earnings #AntibodyMedicines

[Genmab @Genmab]

Happy #NationalInternDay to our incredible Genmab summer interns!

This summer, our interns brought fresh perspectives, curiosity, and enthusiasm to teams across Genmab. From R&D and Commercialization to Data, Digital & AI, Corporate Functions, and other teams across the organization, they collaborated, learned, and made meaningful contributions alongside colleagues.

Thank you to our interns, managers, mentors, and colleagues for making this a rewarding and successful summer!

[Genmab @Genmab]

At the heart of every scientific advancement is a team united by a shared commitment to innovation and collaboration.

In this week's #AntibodyHour 🕙, hear from our colleague Neda Dukanovic Misic, Director, Quality Management & Lab Compliance, Global Lab Management, on how a personal connection to cancer inspires her work supporting the consistency and integrity of our labs—and the science behind potential new medicines.

[Genmab @Genmab]

At Genmab, curiosity and courage drive us to explore bold ideas—always grounded in strong science and teamwork.

During this edition of #AntibodyHour 🕙, our colleague Esil shares how she leads oncology programs from discovery toward the clinic with one goal in mind: bringing potential new medicines to patients.

[Genmab @Genmab]

#News: The EU Commission has granted marketing authorization for one of our therapies, developed with @abbvie, as a combination regimen for adults with relapsed/refractory (R/R) follicular #lymphoma (FL).

Learn more: https://t.co/081yv6g0Tq

[Genmab @Genmab]

#NewsUpdate: Today, topline results are available from a Phase 3 study in relapsed/refractory diffuse large B-cell #lymphoma (#DLBCL), in partnership with @abbvie.

Learn more: https://t.co/oCv3H5sTOq

[Genmab @Genmab]

This Cancer Immunotherapy Month, we’re spotlighting our colleague Erik Voets, Associate Director, Product Discovery Lead at Genmab. Erik works on developing innovative immune-based therapies designed to help the body better recognize and target harmful cells

At Genmab, we aspire to advance innovative antibody therapies to positively impact patients.

Learn more: https://t.co/5ZqCCnNMYT.

#CancerImmunotherapyMonth

[Genmab @Genmab]

During this edition of #AntibodyHour 🕙, Farshid Alemdehy, Senior Scientist in Translational Medicine and Research at Genmab, shares how his team works to bridge preclinical and early clinical development to ensure the science behind our medicines translates into meaningful benefits for patients.

[Genmab @Genmab]

We want to hear from you! Answer the poll below to let us know what topic interests you and what you would like to learn more about?

Please answer below! ⬇️

What makes you feel most connected to a company’s vision?